18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation.
暂无分享,去创建一个
P. Lambin | L. Boersma | D. de Ruysscher | M. Hochstenbag | G. Bootsma | W. Geraedts | C. Pitz | J. Simons | A. Dingemans | G. Snoep | J. V. van Loon | J. Grutters | R. Wanders | B. Brans | Wiel Geraedts
[1] P. Lambin,et al. Follow-up with 18FDG-PET-CT after radical radiotherapy with or without chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung cancer patients: a prospective study. , 2009, European journal of cancer.
[2] M. Halpern,et al. Economic Evaluations of Medical Care Interventions for Cancer Patients: How, Why, and What Does it Mean? , 2008, CA: a cancer journal for clinicians.
[3] G. Bepler,et al. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Joore,et al. Decision-analytic modeling to assist decision making in organizational innovation: the case of shared care in hearing aid provision. , 2007, Health services research.
[5] J. Rubins,et al. Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd edition). , 2007, Chest.
[6] M. Woronoff-Lemsi,et al. Protocole IFCT-0302 : essai randomisé de deux schémas de surveillance dans les cancers bronchiques non à petites cellules complètement réséqués , 2007 .
[7] F. Shepherd,et al. Does Intensive Follow-up Alter Outcome in Patients with Advanced Lung Cancer? , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[8] J. Koeller,et al. Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer. , 2006, The oncologist.
[9] R. Abrams,et al. Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[10] M. Sculpher,et al. Decision Modelling for Health Economic Evaluation , 2006 .
[11] Ping Yang,et al. Long-term survivorship in lung cancer: a review. , 2006, Chest.
[12] J. Matthews,et al. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. , 2005, Lung cancer.
[13] Miklos Pless,et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Dancey,et al. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. , 2004, Lung cancer.
[15] Peter A Ubel,et al. What is the price of life and why doesn't it increase at the rate of inflation? , 2003, Archives of internal medicine.
[16] Danny Rischin,et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] M. Drummond,et al. A rational framework for decision making by the National Institute For Clinical Excellence (NICE) , 2002, The Lancet.
[18] T. Nakajima,et al. Reirradiation for locally recurrent lung cancer previously treated with radiation therapy. , 2002, International journal of radiation oncology, biology, physics.
[19] M. Sculpher,et al. Representing uncertainty: the role of cost-effectiveness acceptability curves. , 2001, Health economics.
[20] S. Tyldesley,et al. Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach. , 2001, International journal of radiation oncology, biology, physics.
[21] J. Dancey,et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] John E. Connolly,et al. Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. , 2000, AJR. American journal of roentgenology.
[23] P. Wingo,et al. Long-term cancer patient survival in the United States. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[24] M. Edelman,et al. The Utility of Follow-up Testing After Curative Cancer Therapy: A Critical Review and Economic Analysis , 1997, Journal of General Internal Medicine.
[25] J R Beck,et al. Markov Models in Medical Decision Making , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.
[26] M. Drummond,et al. Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .
[27] M. Buxton,et al. Economic Evaluation and Decision Making in the UK , 2012, PharmacoEconomics.
[28] Milton C. Weinstein,et al. Recent Developments in Decision-Analytic Modelling for Economic Evaluation , 2012, PharmacoEconomics.
[29] A. Messori,et al. Quality of Life and Utility in Patients with Non-Small Cell Lung Cancer , 2012, PharmacoEconomics.
[30] A. Messori,et al. Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics. , 2001, PharmacoEconomics.